Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 36–37
HOS-118505 · Präparat HOS-094825
36
Tipranavir/ritonavir Maraviroc AUC12 ↔ 1.02
500 mg/200 mg BID Maraviroc Cmax: ↔ 0.86
(maraviroc 150 mg BID) Tipranavir/ritonavir concentrations
were consistent with historical data.
Fosamprenavir/ritonavir Maraviroc AUC12: ↑ 2.49 Concomitant use is not
700 mg/100 mg BID Maraviroc Cmax: ↑ 1.52 recommended. Significant
(maraviroc 300 mg BID) Maraviroc C12: ↑ 4.74 reductions in amprenavir Cmin
observed may result in
Amprenavir AUC12: ↓ 0.65 virological failure in patients
Amprenavir Cmax: ↓ 0.66
Amprenavir C12: ↓ 0.64
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage ccee09d573f90ab6c86c9f2bb8b7a27b4c98027300c8d99f55527da25b029149 · Zeichen 10836–11630 im Abschnitt
Wechselwirkungen · Effentora
Effentora 100 micrograms buccal tablets Effentora 200 micrograms buccal tablets Effentora 400 micrograms buccal tablets Effentora 600 micrograms buccal tablets Effentora 800 micrograms buccal tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-209208 · Präparat HOS-154273
CYP3A4 inhibitors
The concomitant use of Effentora with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole,
itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate CYP3A4 inhibitors (e.g.,
amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:58:00Z · SHA-256 b4a304bd9d2ca3f423d95be522ff20307f46a2ce762379e94c21a56805a240f8 · Passage 0cf5c88c70c4ae39f0d76035db9f738e3de8f9e72008c3bf601dfee4d384ee76 · Zeichen 359–669 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-119734 · Präparat HOS-095005
7
NNRTIs
Efavirenz Combining two NNRTIs has not been shown to It is not recommended to
Nevirapine be beneficial. Concomitant use of etravirine co-administer INTELENCE
Rilpivirine with efavirenz or nevirapine may cause a with other NNRTIs.
significant decrease in the plasma concentration
of etravirine and loss of therapeutic effect of
etravirine.
Concomitant use of etravirine with rilpivirine
may cause a decrease in the plasma
concentration of rilpivirine and loss of
therapeutic effect of rilpivirine.
HIV Protease Inhibitors (PIs) – Unboosted (i.e. without co-administration of low-dose ritonavir)
Indinavir Concomitant use of etravirine with indinavir It is not recommended to
may cause a significant decrease in the plasma co-administer INTELENCE
concentration of indinavir and loss of with indinavir.
therapeutic effect of indinavir.
HIV PIs – Boosted with low-dose ritonavir
Atazanavir/ritonavir atazanavir INTELENCE and
300/100 mg once daily AUC ↓ 0.86 (0.79-0.93) atazanavir/ritonavir can be
Cmin ↓ 0.62 (0.55-0.71) used without dose
Cmax ↔ 0.97 (0.89-1.05) adjustment.
etravirine
AUC ↑ 1.30 (1.18-1.44)
Cmin ↑ 1.26 (1.12-1.42)
Cmax ↑ 1.30 (1.17-1.44)
Darunavir/ritonavir darunavir INTELENCE and
600/100 mg twice daily AUC ↔ 1.15 (1.05-1.26) darunavir/ritonavir can be
Cmin ↔ 1.02 (0.90-1.17) used without dose
Cmax ↔ 1.11 (1.01-1.22) adjustments (see also
etravirine section 5.1).
AUC ↓ 0.63 (0.54-0.73)
Cmin ↓ 0.51 (0.44-0.61)
Cmax ↓ 0.68 (0.57-0.82)
Fosamprenavir/ritonavir amprenavir Amprenavir/ritonavir and
700/100 mg twice daily AUC ↑ 1.69 (1.53-1.86) fosamprenavir/ritonavir may
Cmin ↑ 1.77 (1.39-2.25) require dose reduction when
Cmax ↑ 1.62 (1.47-1.79) co-administered with
etravirine INTELENCE. Using the oral
AUC ↔a solution may be considered
Cmin ↔a for dose reduction.
Cmax ↔a
Lopinavir/ritonavir lopinavir INTELENCE and
(tablet) AUC ↔ 0.87 (0.83-0.92) lopinavir/ritonavir can be
400/100 mg twice daily Cmin ↓ 0.80 (0.73-0.88) used without dose
Cmax ↔ 0.89 (0.82-0.96) adjustments.
etravirine
AUC ↓ 0.65 (0.59-0.71)
Cmin ↓ 0.55 (0.49-0.62)
Cmax ↓ 0.70 (0.64-0.78)
Saquinavir/ritonavir saquinavir INTELENCE and
1,000/100 mg twice daily AUC ↔ 0.95 (0.64-1.42) saquinavir/ritonavir can be
Cmin ↓ 0.80 (0.46-1.38) used without dose
Cmax ↔ 1.00 (0.70-1.42) adjustments.
etravirine
AUC ↓ 0.67 (0.56-0.80)
Cmin ↓ 0.71 (0.58-0.87)
Cmax ↓ 0.63 (0.53-0.75)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) saquinavir (HOS-084522) amprenavir (HOS-086183) rilpivirine (HOS-088090) darunavir (HOS-086181) efavirenz (HOS-087947) nevirapine (HOS-088064) fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 23dfafcde24735cb3cd88681ce12df0c18f7626edad5dad7f7170a308b3611a1 · Zeichen 3986–8467 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7
HOS-120558 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container · Abschnitt 4.5 · PDF-Seite 20
HOS-120583 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 33
HOS-120606 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Afinitor
Afinitor 2.5 mg tablets Afinitor 5 mg tablets Afinitor 10 mg tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-210305 · Präparat HOS-154501
Active substance by Interaction – Change in Recommendations concerning
interaction Everolimus AUC/Cmax co-administration
Geometric mean ratio
(observed range)
Potent CYP3A4/PgP inhibitors
Ketoconazole AUC ↑15.3-fold Concomitant treatment of Afinitor
(range 11.2-22.5) and potent inhibitors is not
Cmax ↑4.1-fold recommended.
(range 2.6-7.0)
Itraconazole, posaconazole, Not studied. Large increase in
voriconazole everolimus concentration is
Telithromycin, expected.
clarithromycin
Nefazodone
Ritonavir, atazanavir,
saquinavir, darunavir,
indinavir, nelfinavir
Moderate CYP3A4/PgP inhibitors
Erythromycin AUC ↑4.4-fold Use caution when
(range 2.0-12.6) co-administration of moderate
Cmax ↑2.0-fold CYP3A4 inhibitors or PgP
(range 0.9-3.5) inhibitors cannot be avoided. If
Imatinib AUC ↑ 3.7-fold patients require co-administration
Cmax ↑ 2.2-fold of a moderate CYP3A4 or PgP
Verapamil AUC ↑3.5-fold inhibitor, dose reduction to 5 mg
(range 2.2-6.3) daily or 2.5 mg daily may be
Cmax ↑2.3-fold considered. However, there are no
(range1.3-3.8) clinical data with this dose
Ciclosporin oral AUC ↑2.7-fold adjustment. Due to between
(range 1.5-4.7) subject variability the
Cmax ↑1.8-fold recommended dose adjustments
(range 1.3-2.6) may not be optimal in all
Cannabidiol (PgP inhibitor) AUC ↑2.5-fold individuals, therefore close
Cmax ↑2.5-fold monitoring of side effects is
Fluconazole Not studied. Increased exposure recommended (see sections 4.2 and
Diltiazem expected. 4.4). If the moderate inhibitor is
Dronedarone Not studied. Increased exposure discontinued, consider a washout
expected. period of at least 2 to 3 days
Amprenavir, fosamprenavir Not studied. Increased exposure (average elimination time for most
expected. commonly used moderate
inhibitors) before the Afinitor dose
is returned to the dose used prior to
initiation of the co-administration.
Grapefruit juice or other Not studied. Increased exposure Combination should be avoided.
food affecting CYP3A4/PgP expected (the effect varies
widely).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T11:21:00Z · SHA-256 678fc33837cd44d2e9320c5c80ffc02496b10803d7810e1b4f6e2d8e517263a0 · Passage 98d9f664e41c1a110308717f9cdec97f696053564a7a56a6d0f4d257ec0e0700 · Zeichen 1007–4534 im Abschnitt
Wechselwirkungen · PecFent
PecFent 100 micrograms/spray nasal spray, solution PecFent 400 micrograms/spray nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7–8
HOS-212292 · Präparat HOS-154864
7
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g. amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
grapefruit juice, and verapamil) may result in increased fentanyl plasma concentrations, potentially
causing serious adverse drug reactions including fatal respiratory depression. Patients receiving
PecFent concomitantly with moderate or strong CYP3A4 inhibitors should be carefully monitored for
an extended period of time. Dose increase should be undertaken with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T09:30:00Z · SHA-256 6c66e20c8a5497199e4a93d57ee169d120fab4ca07ded4b5af9add0ded3852e4 · Passage baea18cdc0d760a3126f0945c5f69a526986b9a3412eefdc3117a24e58041ab8 · Zeichen 656–1232 im Abschnitt
Wechselwirkungen · Brilique
Brilique 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-123512 · Präparat HOS-095701
CYP3A4 inhibitors
• Strong CYP3A4 inhibitors – Co-administration of ketoconazole with ticagrelor increased the
ticagrelor Cmax and AUC equal to 2.4-fold and 7.3-fold, respectively. The Cmax and AUC of the
active metabolite were reduced by 89% and 56%, respectively. Other strong inhibitors of
CYP3A4 (clarithromycin, nefazodone, ritonavir and atazanavir) would be expected to have
similar effects and therefore concomitant use of strong CYP3A4 inhibitors with ticagrelor is
contraindicated (see section 4.3).
• Moderate CYP3A4 inhibitors – Co-administration of diltiazem with ticagrelor increased the
ticagrelor Cmax by 69% and AUC to 2.7-fold and decreased the active metabolite Cmax by 38%
and AUC was unchanged. There was no effect of ticagrelor on diltiazem plasma levels. Other
moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, erythromycin and fluconazole)
would be expected to have a similar effect and can as well be co-administered with ticagrelor.
• A 2-fold increase of ticagrelor exposure was observed after daily consumption of large
quantities of grapefruit juice (3 x 200 ml). This magnitude of increased exposure is not
expected to be clinically relevant to most patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:59:00Z · SHA-256 f815638059a70571d33a6ddc4107523f2ae567aafc2b20551ad4a9b0fb2f2aca · Passage 46ef36c35bfbcc3b76ae28d130f6972295d68dc0c9bfdb2a9ad0b405339e0267 · Zeichen 327–1572 im Abschnitt
Wechselwirkungen · Brilique
Brilique 90 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-123576 · Präparat HOS-095701
CYP3A4 inhibitors
• Strong CYP3A4 inhibitors – Co-administration of ketoconazole with ticagrelor increased the
ticagrelor Cmax and AUC equal to 2.4-fold and 7.3-fold, respectively. The Cmax and AUC of the
active metabolite were reduced by 89% and 56%, respectively. Other strong inhibitors of
CYP3A4 (clarithromycin, nefazodone, ritonavir and atazanavir) would be expected to have
similar effects and therefore concomitant use of strong CYP3A4 inhibitors with ticagrelor is
contraindicated (see section 4.3).
• Moderate CYP3A4 inhibitors – Co-administration of diltiazem with ticagrelor increased the
ticagrelor Cmax by 69% and AUC to 2.7-fold and decreased the active metabolite Cmax by 38%
and AUC was unchanged. There was no effect of ticagrelor on diltiazem plasma levels. Other
moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, erythromycin and fluconazole)
would be expected to have a similar effect and can as well be co-administered with ticagrelor.
• A 2-fold increase of ticagrelor exposure was observed after daily consumption of large
quantities of grapefruit juice (3 x 200 ml). This magnitude of increased exposure is not
expected to be clinically relevant to most patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:59:00Z · SHA-256 f815638059a70571d33a6ddc4107523f2ae567aafc2b20551ad4a9b0fb2f2aca · Passage 46ef36c35bfbcc3b76ae28d130f6972295d68dc0c9bfdb2a9ad0b405339e0267 · Zeichen 327–1572 im Abschnitt
Wechselwirkungen · Brilique
Brilique 90 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-123631 · Präparat HOS-095701
CYP3A4 inhibitors
• Strong CYP3A4 inhibitors – Co-administration of ketoconazole with ticagrelor increased the
ticagrelor Cmax and AUC equal to 2.4-fold and 7.3-fold, respectively. The Cmax and AUC of the
active metabolite were reduced by 89% and 56%, respectively. Other strong inhibitors of
CYP3A4 (clarithromycin, nefazodone, ritonavir and atazanavir) would be expected to have
similar effects and therefore concomitant use of strong CYP3A4 inhibitors with ticagrelor is
contraindicated (see section 4.3).
• Moderate CYP3A4 inhibitors – Co-administration of diltiazem with ticagrelor increased the
ticagrelor Cmax by 69% and AUC to 2.7-fold and decreased the active metabolite Cmax by 38%
and AUC was unchanged. There was no effect of ticagrelor on diltiazem plasma levels. Other
moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, erythromycin and fluconazole)
would be expected to have a similar effect and can as well be co-administered with ticagrelor.
• A 2-fold increase of ticagrelor exposure was observed after daily consumption of large
quantities of grapefruit juice (3 x 200 ml). This magnitude of increased exposure is not
expected to be clinically relevant to most patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:59:00Z · SHA-256 f815638059a70571d33a6ddc4107523f2ae567aafc2b20551ad4a9b0fb2f2aca · Passage 46ef36c35bfbcc3b76ae28d130f6972295d68dc0c9bfdb2a9ad0b405339e0267 · Zeichen 327–1572 im Abschnitt
Wechselwirkungen · Votubia
Votubia 2.5 mg tablets Votubia 5 mg tablets Votubia 10 mg tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-214256 · Präparat HOS-155312
Active substance by Interaction – Change in Recommendations concerning
interaction Everolimus AUC/Cmax co-administration
Geometric mean ratio
(observed range)
Potent CYP3A4/PgP inhibitors
Ketoconazole AUC ↑15.3-fold Concomitant treatment of Votubia
(range 11.2-22.5) and potent inhibitors is not
Cmax ↑4.1-fold recommended.
(range 2.6-7.0)
Itraconazole, posaconazole, Not studied. Large increase in
voriconazole everolimus concentration is
Telithromycin, expected.
clarithromycin
Nefazodone
Ritonavir, atazanavir,
saquinavir, darunavir,
indinavir, nelfinavir
Moderate CYP3A4/PgP inhibitors
Erythromycin AUC ↑4.4-fold Use caution when co-administration
(range 2.0-12.6) of moderate CYP3A4 inhibitors or
Cmax ↑2.0-fold PgP inhibitors cannot be avoided.
(range 0.9-3.5)
Imatinib AUC ↑ 3.7-fold For patients with renal
Cmax ↑ 2.2-fold angiomyolipoma associated with
Verapamil AUC ↑3.5-fold TSC:
(range 2.2-6.3) If patients require co-administration
Cmax ↑2.3-fold of a moderate CYP3A4 or PgP
(range1.3-3.8) inhibitor, dose reduction to 5 mg or
Ciclosporin oral AUC ↑2.7-fold 2.5 mg daily may be considered.
(range 1.5-4.7) However, there are no clinical data
Cmax ↑1.8-fold with this dose adjustment. Due to
(range 1.3-2.6) between subject variability the
Cannabidiol (PgP inhibitor) AUC ↑2.5-fold recommended dose adjustments may
Cmax ↑2.5-fold not be optimal in all individuals,
Fluconazole Not studied. Increased exposure therefore close monitoring of side
Diltiazem expected. effects is recommended. If the
Dronedarone Not studied. Increased exposure moderate inhibitor is discontinued,
expected. consider a washout period of at least
Amprenavir, fosamprenavir Not studied. Increased exposure 2 to 3 days (average elimination time
expected. for most commonly used moderate
inhibitors) before the Votubia dose is
returned to the dose used prior to
initiation of the co-administration
(see also Therapeutic drug
monitoring in section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T17:40:00Z · SHA-256 252b066ec590fdab1f3eb7eccacdb5c7e91ec79421c970096d1b5261820faba4 · Passage 874bc02290752e0fb541064d49638c0e5fad0c860b7d55032749ccc1bff1dcda · Zeichen 1008–4464 im Abschnitt
Wechselwirkungen · Votubia
Votubia 1 mg dispersible tablets Votubia 2 mg dispersible tablets Votubia 3 mg dispersible tablets Votubia 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 38
HOS-214306 · Präparat HOS-155312
Active substance by Interaction – Change in Recommendations concerning
interaction Everolimus AUC/Cmax co-administration
Geometric mean ratio
(observed range)
Potent CYP3A4/PgP inhibitors
Ketoconazole AUC ↑15.3-fold Concomitant treatment of Votubia
(range 11.2-22.5) and potent inhibitors is not
Cmax ↑4.1-fold recommended.
(range 2.6-7.0)
Itraconazole, posaconazole, Not studied. Large increase in
voriconazole everolimus concentration is
Telithromycin, expected.
clarithromycin
Nefazodone
Ritonavir, atazanavir,
saquinavir, darunavir,
indinavir, nelfinavir
Moderate CYP3A4/PgP inhibitors
Erythromycin AUC ↑4.4-fold Use caution when co-administration
(range 2.0-12.6) of moderate CYP3A4 inhibitors or
Cmax ↑2.0-fold PgP inhibitors cannot be avoided.
(range 0.9-3.5)
Imatinib AUC ↑ 3.7-fold If patients require co-administration
Cmax ↑ 2.2-fold of a moderate CYP3A4 or PgP
Verapamil AUC ↑3.5-fold inhibitor, reduce the daily dose by
(range 2.2-6.3) approximately 50%. Further dose
Cmax ↑2.3-fold reduction may be required to manage
(range1.3-3.8) adverse reactions (see sections 4.2
Ciclosporin oral AUC ↑2.7-fold and 4.4). Everolimus trough
(range 1.5-4.7) concentrations should be assessed at
Cmax ↑1.8-fold least 1 week after the addition of a
(range 1.3-2.6) moderate CYP3A4 or PgP inhibitor.
Cannabidiol (PgP inhibitor) AUC ↑2.5-fold If the moderate inhibitor is
Cmax ↑2.5-fold discontinued, consider a washout
Fluconazole Not studied. Increased exposure period of at least 2 to 3 days
Diltiazem expected. (average elimination time for most
Dronedarone Not studied. Increased exposure commonly used moderate inhibitors)
expected. before the Votubia dose is returned
Amprenavir, fosamprenavir Not studied. Increased exposure to the dose used prior to initiation of
expected. the co-administration. The
everolimus trough concentration
should be assessed at least 1 week
later (see sections 4.2 and 4.4).
Grapefruit juice or other Not studied. Increased exposure Combination should be avoided.
food affecting CYP3A4/PgP expected (the effect varies
widely).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T17:40:00Z · SHA-256 252b066ec590fdab1f3eb7eccacdb5c7e91ec79421c970096d1b5261820faba4 · Passage ddc95e209a3f4d8e5376fa36e344d27d483981c2f805f567ef2fb4a51b8f3e0c · Zeichen 1012–4524 im Abschnitt
Wechselwirkungen · Bosulif
Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets Bosulif 50 mg hard capsules Bosulif 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-125439 · Präparat HOS-096073
CYP3A inhibitors
The concomitant use of bosutinib with strong CYP3A inhibitors (including, but not limited to
itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, nefazodone,
mibefradil, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, boceprevir, telaprevir,
grapefruit products including grapefruit juice) or moderate CYP3A inhibitors (including, but not
limited to fluconazole, ciprofloxacin, erythromycin, diltiazem, verapamil, amprenavir, atazanavir,
darunavir/ritonavir, fosamprenavir, aprepitant, crizotinib, imatinib) should be avoided, as an increase
in bosutinib plasma concentration will occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) lopinavir (HOS-086269) atazanavir (HOS-086180) nelfinavir (HOS-084520) ciprofloxacin (HOS-085177) ketoconazole (HOS-084513) crizotinib (HOS-116818) aprepitant (HOS-112506) mibefradil (HOS-125440) grapefruit juice (HOS-088787) imatinib (HOS-110212) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) bosutinib (HOS-109449) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:15:00Z · SHA-256 86c38605c3386630b4591643bb4507bc13ee17f96b594c991ef48865ec55c6c0 · Passage bf891fc27dae495286d0ddabf1a684337d5b862d791c1636c6fade4c46be3a59 · Zeichen 50–707 im Abschnitt
Wechselwirkungen · Jakavi
Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-126113 · Präparat HOS-096217
Mild or moderate CYP3A4 inhibitors (such as, but not limited to, ciprofloxacin, erythromycin,
amprenavir, atazanavir, diltiazem, cimetidine)
In healthy subjects co-administration of ruxolitinib (10 mg single dose) with erythromycin 500 mg
twice daily for four days resulted in ruxolitinib Cmax and AUC that were higher by 8% and 27%,
respectively, than with ruxolitinib alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) atazanavir (HOS-086180) ciprofloxacin (HOS-085177) cimetidine (HOS-085835) erythromycin (HOS-084514) amprenavir (HOS-086183)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-10T13:51:00Z · SHA-256 f5e9d15f087df0766ff15826906abe609cecf3c8ef177236024d00e93ae36c17 · Passage 1440f7ab0885e7d02b3ca5b24f9fff63d90a9a3beb11153ca96224dfd82a3e76 · Zeichen 2805–3181 im Abschnitt
Wechselwirkungen · Jakavi
Jakavi 5 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 43
HOS-126207 · Präparat HOS-096217
Mild or moderate CYP3A4 inhibitors (such as, but not limited to, ciprofloxacin, erythromycin,
amprenavir, atazanavir, diltiazem, cimetidine)
In healthy subjects co-administration of ruxolitinib (10 mg single dose) with erythromycin 500 mg
twice daily for four days resulted in ruxolitinib Cmax and AUC that were higher by 8% and 27%,
respectively, than with ruxolitinib alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) atazanavir (HOS-086180) ciprofloxacin (HOS-085177) cimetidine (HOS-085835) erythromycin (HOS-084514) amprenavir (HOS-086183)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-10T13:51:00Z · SHA-256 f5e9d15f087df0766ff15826906abe609cecf3c8ef177236024d00e93ae36c17 · Passage 1440f7ab0885e7d02b3ca5b24f9fff63d90a9a3beb11153ca96224dfd82a3e76 · Zeichen 2805–3181 im Abschnitt
Wechselwirkungen · Spedra
Spedra 50 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-127426 · Präparat HOS-096405
Erythromycin (500 mg twice daily), a moderate CYP3A4 inhibitor, increased avanafil 200 mg single-
dose Cmax and AUC equal to approximately 2-fold and 3-fold, respectively, and prolonged the half-life
of avanafil to approximately 8 hours. Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant,
diltiazem, fluconazole, fosamprenavir, and verapamil) would be expected to have similar effects.
Consequently, the maximum recommended dose of avanafil is 100 mg, not to exceed once every
48 hours for patients taking concomitant moderate CYP3A4 inhibitors (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) aprepitant (HOS-112506) fluconazole (HOS-087945) erythromycin (HOS-084514) amprenavir (HOS-086183) fosamprenavir (HOS-086182) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage 7862c7ccd386d34bcf7cd1ade08e789c5ba94b3dce3f3441a4c6659cf1964b59 · Zeichen 5327–5902 im Abschnitt
Wechselwirkungen · Spedra
Spedra 100 mg tablets · Abschnitt 4.5 · PDF-Seite 19
HOS-127470 · Präparat HOS-096405
Erythromycin (500 mg twice daily), a moderate CYP3A4 inhibitor, increased avanafil 200 mg single-
dose Cmax and AUC equal to approximately 2-fold and 3-fold, respectively, and prolonged the half-life
of avanafil to approximately 8 hours. Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant,
diltiazem, fluconazole, fosamprenavir, and verapamil) would be expected to have similar effects.
Consequently, the maximum recommended dose of avanafil is 100 mg, not to exceed once every
48 hours for patients taking concomitant moderate CYP3A4 inhibitors (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) aprepitant (HOS-112506) fluconazole (HOS-087945) erythromycin (HOS-084514) amprenavir (HOS-086183) fosamprenavir (HOS-086182) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage 7862c7ccd386d34bcf7cd1ade08e789c5ba94b3dce3f3441a4c6659cf1964b59 · Zeichen 5328–5903 im Abschnitt
Wechselwirkungen · Spedra
Spedra 200 mg tablets · Abschnitt 4.5 · PDF-Seite 32
HOS-127514 · Präparat HOS-096405
Erythromycin (500 mg twice daily), a moderate CYP3A4 inhibitor, increased avanafil 200 mg single-
dose Cmax and AUC equal to approximately 2-fold and 3-fold, respectively, and prolonged the half-life
of avanafil to approximately 8 hours. Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant,
diltiazem, fluconazole, fosamprenavir, and verapamil) would be expected to have similar effects.
Consequently, the maximum recommended dose of avanafil is 100 mg, not to exceed once every
48 hours for patients taking concomitant moderate CYP3A4 inhibitors (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) aprepitant (HOS-112506) fluconazole (HOS-087945) erythromycin (HOS-084514) amprenavir (HOS-086183) fosamprenavir (HOS-086182) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:55:00Z · SHA-256 9f3a1264ef001d577393feb260b99952ed079148f452f8976f0be132f469d380 · Passage 7862c7ccd386d34bcf7cd1ade08e789c5ba94b3dce3f3441a4c6659cf1964b59 · Zeichen 5328–5903 im Abschnitt
Wechselwirkungen · Nexium Control
Nexium Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-127699 · Präparat HOS-096457
For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported
during concomitant omeprazole treatment (40 mg once a day). Treatment with omeprazole 20 mg once
a day had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with
concomitant ritonavir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): saquinavir (HOS-084522) amprenavir (HOS-086183) darunavir (HOS-086181) ritonavir (HOS-084521) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:26:00Z · SHA-256 d4554b4b11397de3effc8bd7e120a7d0370b488e26268f079cad37ef37aaaf22 · Passage 86c3b4131e94b12bb433cb615338f456d42b34a2151ab4968d1bd2735adf4a05 · Zeichen 1984–2300 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.